Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$207M+6.7%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$10.64M+79.1%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.34M-8.3%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1.09M+44.0%
Biohaven logo
BiohavenBHVN
$5.9M+25.3%
Septerna, Inc. logo
Septerna, Inc.SEPN
$2.41M+18.9%

Other financials

Income statement

See full
Revenue-—
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.18B+319%
Enterprise value$2.13B+345%
P/S109.1×—

Profitability

See full
Operating margin-767.6%—
Net margin-685.8%—
FCF margin-485.7%—

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0×0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemJune 30,2026December 31,2025
Current liabilities
Accounts payable$2,796$4,190
Accrued expenses and other current liabilities23,15512,104
Operating lease liability2,4732,755
Total current liabilities28,42419,049
Operating lease liability, net of current portion7,6328,729
Total liabilities36,05627,778
Commitments and contingencies (Note 10)

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s operating lease liabilities (current)?
Rapport Therapeutics, Inc. (RAPP) reported operating lease liabilities (current) of $2.47M in Q2 2026.
How has Rapport Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?
Rapport Therapeutics, Inc.'s operating lease liabilities (current) increased by 40.6% year-over-year, from $1.76M to $2.47M.
What is the long-term trend for Rapport Therapeutics, Inc.'s operating lease liabilities (current)?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 102.8% compound annual growth rate (CAGR), from $670K to $2.76M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Rapport Therapeutics, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude